Answers are grounded in this paper and cite their sources.
The paper elaborates on the leeway left by the Agreement on Trade Related Aspects of Intellectual Property Rights to determine how the patentability requirements are applied, particularly for pharmaceuticals. In addition to claims on the active ingredients as such, numerous patents are applied in relation to pharmaceutical formulations, compositions, combinations, dosage forms, salts, polymorphs, optical isomers, metabolites, etc. Often claims encompass large families of compounds while 'selection patents' cover a sub-group of previously disclosed compounds. The paper also briefly considers the case of second pharmaceutical indications. It contains some recommendations to handle these issues, taking public health interests into account.
No takes yet. Share an insight, caveat, or question.
Carlos M. Correa (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: